Data from Clinicaltrials.gov - Curated by Toby Galbraith - Last updated 16 February 2017

This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066/ABBV-066...

purpose

This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
 
Category Value
Date last updated at source 31-Jan-17
Study type(s) Interventional
Expected enrolment 500
Study start date 01-Feb-16
Estimated primary completion date 01-Sep-17

View full details

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Related Content